119 related articles for article (PubMed ID: 20874647)
1. Leflunomide: a drug with a potential beyond rheumatology.
Teschner S; Burst V
Immunotherapy; 2010 Sep; 2(5):637-50. PubMed ID: 20874647
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of leflunomide in rheumatoid arthritis.
Fox RI
J Rheumatol Suppl; 1998 Jul; 53():20-6. PubMed ID: 9666414
[TBL] [Abstract][Full Text] [Related]
3. Leflunomide Aventis Pharma.
Kaplan MJ
Curr Opin Investig Drugs; 2001 Feb; 2(2):222-30. PubMed ID: 11816835
[TBL] [Abstract][Full Text] [Related]
4. Leflunomide use in renal transplantation.
Leca N
Curr Opin Organ Transplant; 2009 Aug; 14(4):370-4. PubMed ID: 19512928
[TBL] [Abstract][Full Text] [Related]
5. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.
Pawlik A; Herczynska M; Kurzawski M; Safranow K; Dziedziejko V; Drozdzik M
Pharmacogenomics; 2009 Feb; 10(2):303-9. PubMed ID: 19207032
[TBL] [Abstract][Full Text] [Related]
6. Leflunomide.
Cannon GW; Kremer JM
Rheum Dis Clin North Am; 2004 May; 30(2):295-309, vi. PubMed ID: 15172042
[TBL] [Abstract][Full Text] [Related]
7. Leflunomide: dermatologic perspective.
Sehgal VN; Verma P
J Dermatolog Treat; 2013 Apr; 24(2):89-95. PubMed ID: 21801113
[TBL] [Abstract][Full Text] [Related]
8. Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.
Leban J; Vitt D
Arzneimittelforschung; 2011; 61(1):66-72. PubMed ID: 21355448
[TBL] [Abstract][Full Text] [Related]
9. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Cherwinski HM; Cohn RG; Cheung P; Webster DJ; Xu YZ; Caulfield JP; Young JM; Nakano G; Ransom JT
J Pharmacol Exp Ther; 1995 Nov; 275(2):1043-9. PubMed ID: 7473131
[TBL] [Abstract][Full Text] [Related]
10. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection.
Savikko J; Von Willebrand E; Häyry P
Transplantation; 2003 Aug; 76(3):455-8; discussion 471-3. PubMed ID: 12923428
[TBL] [Abstract][Full Text] [Related]
11. Leflunomide or methotrexate for juvenile rheumatoid arthritis.
Silverman E; Mouy R; Spiegel L; Jung LK; Saurenmann RK; Lahdenne P; Horneff G; Calvo I; Szer IS; Simpson K; Stewart JA; Strand V;
N Engl J Med; 2005 Apr; 352(16):1655-66. PubMed ID: 15843668
[TBL] [Abstract][Full Text] [Related]
12. Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.
Behrens F; Koehm M; Burkhardt H
Curr Opin Rheumatol; 2011 May; 23(3):282-7. PubMed ID: 21427581
[TBL] [Abstract][Full Text] [Related]
13. Can leflunomide play a role in cytomegalovirus disease prophylaxis besides its antirheumatic effects?
Lu CH; Tsai JH; Wu MZ; Yu CL; Hsieh SC
Antivir Ther; 2015; 20(1):93-6. PubMed ID: 24831792
[TBL] [Abstract][Full Text] [Related]
14. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
Herrmann ML; Schleyerbach R; Kirschbaum BJ
Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294
[TBL] [Abstract][Full Text] [Related]
15. Leflunomide in clinical practice.
Pinto P; Dougados M
Acta Reumatol Port; 2006; 31(3):215-24. PubMed ID: 17094333
[TBL] [Abstract][Full Text] [Related]
16. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
[TBL] [Abstract][Full Text] [Related]
17. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis.
Grabar PB; Rozman B; Logar D; Praprotnik S; Dolzan V
Ann Rheum Dis; 2009 Aug; 68(8):1367-8. PubMed ID: 19605743
[No Abstract] [Full Text] [Related]
18. Leflunomide in Pakistani patients with rheumatoid arthritis: prospective study in daily rheumatology practice.
Ahmad NM; Farman S; Saeed MA; Hameed R; Umair M; Ghafoor E
Int J Rheum Dis; 2011 Feb; 14(1):48-54. PubMed ID: 21303481
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting the teratogenicity of the immunosuppressant leflunomide in mice by supplementation of exogenous uridine.
Fukushima R; Kanamori S; Hirashiba M; Hishikawa A; Muranaka R; Kaneto M; Kitagawa H
Toxicol Sci; 2009 Apr; 108(2):419-26. PubMed ID: 19190124
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.
Kalden JR; Schattenkirchner M; Sörensen H; Emery P; Deighton C; Rozman B; Breedveld F
Arthritis Rheum; 2003 Jun; 48(6):1513-20. PubMed ID: 12794818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
